Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

526 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
Roberts SC, Jain S, Tremoulet AH, Kim KK, Burns JC; KIDCARE Multicenter Study Group; Anand V, Anderson M, Ang J, Ansusinha E, Arditi M, Ashouri N, Bartlett A, Chatterjee A, DeBiasi R, Dekker C, DeZure C, Didion L, Dominguez S, El Feghaly R, Erdem G, Halasa N, Harahsheh A, Jackson MA, Jaggi P, Jain S, Jone PN, Kaushik N, Kurio G, Lillian A, Lloyd D, Manaloor J, McNelis A, Michalik DE, Newburger J, Newcomer C, Perkins T, Portman M, Romero J, Ronis T, Rowley A, Schneider K, Schuster J, Tejtel SKS, Sharma K, Simonsen K, Szmuszkovicz J, Truong D, Wood J, Yeh S. Roberts SC, et al. Among authors: dekker c. Contemp Clin Trials. 2019 Apr;79:98-103. doi: 10.1016/j.cct.2019.02.008. Epub 2019 Mar 3. Contemp Clin Trials. 2019. PMID: 30840903 Free article.
Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, Jain SS, Michalik DE, Sharma K, Truong DT, Wood JB, Kim KK, Jain S; KIDCARE Multicenter Study Group. Burns JC, et al. Lancet Child Adolesc Health. 2021 Dec;5(12):852-861. doi: 10.1016/S2352-4642(21)00270-4. Epub 2021 Oct 27. Lancet Child Adolesc Health. 2021. PMID: 34715057 Free article. Clinical Trial.
Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.
Carter C, Houser KV, Yamshchikov GV, Bellamy AR, May J, Enama ME, Sarwar U, Larkin B, Bailer RT, Koup R, Chen GL, Patel SM, Winokur P, Belshe R, Dekker CL, Graham BS, Ledgerwood JE; VRC 703 study team. Carter C, et al. Among authors: dekker cl. PLoS One. 2019 Sep 18;14(9):e0222178. doi: 10.1371/journal.pone.0222178. eCollection 2019. PLoS One. 2019. PMID: 31532789 Free PMC article. Clinical Trial.
Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009.
Williams SE, Klein NP, Halsey N, Dekker CL, Baxter RP, Marchant CD, LaRussa PS, Sparks RC, Tokars JI, Pahud BA, Aukes L, Jakob K, Coronel S, Choi H, Slade BA, Edwards KM. Williams SE, et al. Among authors: dekker cl. Vaccine. 2011 Sep 16;29(40):6920-7. doi: 10.1016/j.vaccine.2011.07.044. Epub 2011 Jul 27. Vaccine. 2011. PMID: 21801776 Free PMC article. Review.
Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination.
Williams SE, Pahud BA, Vellozzi C, Donofrio PD, Dekker CL, Halsey N, Klein NP, Baxter RP, Marchant CD, Larussa PS, Barnett ED, Tokars JI, McGeeney BE, Sparks RC, Aukes LL, Jakob K, Coronel S, Sejvar JJ, Slade BA, Edwards KM. Williams SE, et al. Among authors: dekker cl. Vaccine. 2011 Oct 26;29(46):8302-8. doi: 10.1016/j.vaccine.2011.08.093. Epub 2011 Sep 3. Vaccine. 2011. PMID: 21893148 Free PMC article.
Biologically plausible and evidence-based risk intervals in immunization safety research.
Rowhani-Rahbar A, Klein NP, Dekker CL, Edwards KM, Marchant CD, Vellozzi C, Fireman B, Sejvar JJ, Halsey NA, Baxter R; Risk Interval Working Group of the Clinical Immunization Safety Assessment Network. Rowhani-Rahbar A, et al. Among authors: dekker cl. Vaccine. 2012 Dec 17;31(1):271-7. doi: 10.1016/j.vaccine.2012.07.024. Epub 2012 Jul 24. Vaccine. 2012. PMID: 22835735 Review.
Clinical assessment of serious adverse events in children receiving 2009 H1N1 vaccination.
Pahud BA, Williams SE, Dekker CL, Halsey N, Larussa P, Baxter RP, Klein NP, Marchant CD, Sparks RC, Jakob K, Aukes L, Swope S, Barnett E, Lewis P, Berger M, Dreskin SC, Donofrio PD, Sejvar JJ, Slade BA, Gidudu J, Vellozzi C, Edwards KM. Pahud BA, et al. Among authors: dekker cl. Pediatr Infect Dis J. 2013 Feb;32(2):163-8. doi: 10.1097/INF.0b013e318271b90a. Pediatr Infect Dis J. 2013. PMID: 23334340
Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS.
Halsey NA, Griffioen M, Dreskin SC, Dekker CL, Wood R, Sharma D, Jones JF, LaRussa PS, Garner J, Berger M, Proveaux T, Vellozzi C; Hypersensitivity Working Group of the Clinical Immunization Safety Assessment Network; Broder K, Setse R, Pahud B, Hrncir D, Choi H, Sparks R, Williams SE, Engler RJ, Gidudu J, Baxter R, Klein N, Edwards K, Cano M, Kelso JM. Halsey NA, et al. Among authors: dekker cl. Vaccine. 2013 Dec 9;31(51):6107-12. doi: 10.1016/j.vaccine.2013.09.066. Epub 2013 Oct 8. Vaccine. 2013. PMID: 24120547
526 results